|Bid||0.00 x 4000|
|Ask||0.00 x 800|
|Day's Range||5.51 - 5.80|
|52 Week Range||0.94 - 7.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 2, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.96|
ArQule, Inc. (ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the public offering price of $5.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 12,650,000 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQule, to approximately $70 million. Needham & Company, LLC acted as lead co-manager, and Roth Capital Partners, B. Riley FBR and JonesTrading Institutional Services LLC acted as co-managers for the offering.
On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...
ArQule’s (ARQL) product candidates include ARQ 531, which is in Phase 1 for B-cell malignancies refractory to other therapeutic options. Its product candidates also include ARQ 092, which is in a Phase 1 Part 2 study for rare overgrowth diseases and Phase 1 for Proteus syndrome, which is a rare disease.
ArQule, Inc. (ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1.65 million shares of its common stock. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $60.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by ArQule.
ArQule, Inc. (ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ArQule’s (ARQL) research pipeline is focused on molecular targets and biological processes that have a role in the development of human cancers and rare diseases. With the exception of derazantinib, all the compounds in its pipeline are owned by ArQule. In February, ArQule entered into a derazantinib license agreement with Sinovant Sciences, which is a subsidiary of Roivant Sciences.
ArQule’s first-quarter revenues included $3.0 million received from Roivant as an upfront payment for a February agreement. ArQule is expected to generate revenues of $16.97 million in fiscal 2018, $5.84 million in fiscal 2019, and $12.76 million in fiscal 2020. In the first quarter, ArQule (ARQL) incurred research and development expenses of $5.81 million compared with $5.19 million in the first quarter of 2017.
ArQule (ARQL) is a biopharmaceutical company with a focus on developing therapeutics for treating cancers and rare diseases. A leader in precision medical research, ArQule has five product candidates in its research pipeline.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) Quest Diagnostics Inc (NYSE: DGX )(Barclays upgraded shares ...
ArQule, Inc. (ARQL) today announced that it has been added to the Russell 2000® Index, a subset of the Russell 3000® Index, effective as of market closing on June 22, 2018, at the conclusion of the annual Russell US Index reconstitution. "Being included in the Russell Index listings both increases visibility among the investment community and reflects the value ArQule creates for its shareholders," said Paolo Pucci, Chief Executive Officer of ArQule. The Russell 3000® Index measures the performance of the largest 3,000 U.S. companies, which represents approximately 98% of the investable U.S. equity market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 14) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
ArQule, Inc. (ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 23rd Congress of European Hematological Association (EHA) in Stockholm, Sweden. “Preliminary data from our Phase 1 dose escalation trial highlights the potential of ARQ 531 to become a new therapeutic option for patients with B-cell malignancies,” commented ArQule Chief Medical Officer and Head of Research and Development, Brian Schwartz, M.D. “There is a significant unmet need for patients with relapsed or refractory B-cell malignancies, in particular those with C481S-mediated resistance to irreversible BTK inhibitors such as ibrutinib.
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The JMP Securities Life Sciences Conference on June 21, 2018, at 10:30am EDT at the St. Regis in New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
ArQule, Inc. (NASDAQ: ARQL ) shares are up 367 percent year-over-year, but they’re still undervalued, according to Oppenheimer. The Rating Analyst Hartaj Singh initiated coverage on ArQule with an Outperform ...
The company announced that clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies would be presented on June 15, 2018, at the EHA Congress in Stockholm, Sweden. Basilea will be responsible for all costs and expenses of development, manufacture, and commercialization in its territory.
NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Qudian ...
ArQule, Inc. (ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA Congress in Stockholm, Sweden. ARQ 531 is an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Jefferies 2018 Healthcare Conference on June 7, 2018, at 3:00 p.m. ET at the Grand Hyatt, New York, New York. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.
ArQule, Inc. (ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance, and Dr. Shirish Hirani as senior vice president, program management and product planning. “We are delighted to welcome both Marc and Shirish to ArQule’s executive team,” commented ArQule CEO, Paolo Pucci.